SK65794A3 - Pharmaceutical mixture, method of its preparing and using - Google Patents

Pharmaceutical mixture, method of its preparing and using Download PDF

Info

Publication number: SK65794A3
Authority: SK; Slovakia
Prior art keywords: pharmaceutically acceptable; compound; acceptable salt; benzopyran; dihydro
Prior art date: 1991-12-05

Application number

SK657-94A

Other languages

English (en)

Slovak (sk)

Inventor

Jonathan R S Arch

Nicholas E Bowring

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-05

Filing date

1992-12-01

Publication date

1995-02-08

1991-12-05 Priority claimed from GB919125862A external-priority patent/GB9125862D0/en

1992-06-19 Priority claimed from GB929213042A external-priority patent/GB9213042D0/en

1992-12-01 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1995-02-08 Publication of SK65794A3 publication Critical patent/SK65794A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 28
238000000034 method Methods 0.000 title claims abstract description 10
150000001875 compounds Chemical class 0.000 claims abstract description 35
150000003839 salts Chemical class 0.000 claims abstract description 22
239000012453 solvate Substances 0.000 claims abstract description 20
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
239000003937 drug carrier Substances 0.000 claims abstract description 12
239000003814 drug Substances 0.000 claims abstract description 5
239000004480 active ingredient Substances 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 9
208000018569 Respiratory Tract disease Diseases 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 5
208000000884 Airway Obstruction Diseases 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
239000006199 nebulizer Substances 0.000 claims description 4
-1 2-oxopiperidin-1-yl Chemical group 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
ZSUFQZNGDIXQAD-CABCVRRESA-N 1-[(3s,4r)-3-hydroxy-2,2-dimethyl-6-(1,1,2,2,2-pentafluoroethyl)-3,4-dihydrochromen-4-yl]piperidin-2-one Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C(F)(F)C(F)(F)F)CCCCC1=O ZSUFQZNGDIXQAD-CABCVRRESA-N 0.000 claims 3
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 2
YNYNCZFGMLIOJV-UHFFFAOYSA-N C1=CC=C2C=C(O)C(CC)OC2=C1 Chemical compound C1=CC=C2C=C(O)C(CC)OC2=C1 YNYNCZFGMLIOJV-UHFFFAOYSA-N 0.000 claims 1
230000000241 respiratory effect Effects 0.000 claims 1
239000011230 binding agent Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 4
229960002329 methacholine Drugs 0.000 description 4
239000003826 tablet Substances 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229940055577 oleyl alcohol Drugs 0.000 description 2
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
ZSUFQZNGDIXQAD-UHFFFAOYSA-N OC1C(C)(C)OC2=CC=C(C(F)(F)C(F)(F)F)C=C2C1N1CCCCC1=O Chemical compound OC1C(C)(C)OC2=CC=C(C(F)(F)C(F)(F)F)C=C2C1N1CCCCC1=O ZSUFQZNGDIXQAD-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
150000001562 benzopyrans Chemical class 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229960001268 isoetarine Drugs 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000001603 reducing effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK657-94A 1991-12-05 1992-12-01 Pharmaceutical mixture, method of its preparing and using SK65794A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB919125862A GB9125862D0 (en)	1991-12-05	1991-12-05	Pharmaceutical composition
GB929213042A GB9213042D0 (en)	1992-06-19	1992-06-19	Pharmaceutical composition
PCT/GB1992/002234 WO1993010757A1 (fr)	1991-12-05	1992-12-01	Composition pharmaceutique

Publications (1)

Publication Number	Publication Date
SK65794A3 true SK65794A3 (en)	1995-02-08

Family

ID=26299960

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK657-94A SK65794A3 (en)	1991-12-05	1992-12-01	Pharmaceutical mixture, method of its preparing and using

Country Status (15)

Country	Link
EP (1)	EP0615437A1 (fr)
JP (1)	JPH07501538A (fr)
AP (1)	AP382A (fr)
AU (1)	AU2954292A (fr)
BR (1)	BR9206845A (fr)
CA (1)	CA2125156A1 (fr)
CZ (1)	CZ136394A3 (fr)
HU (1)	HUT70745A (fr)
IL (1)	IL103952A0 (fr)
MA (1)	MA22731A1 (fr)
MX (1)	MX9206975A (fr)
RU (1)	RU94030464A (fr)
SI (1)	SI9200365A (fr)
SK (1)	SK65794A3 (fr)
WO (1)	WO1993010757A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE23718T1 (de) *	1981-09-25	1986-12-15	Beecham Group Plc	Benzopyran-verbindungen mit pharmazeutischer wirkung.
EP0093535B1 (fr) *	1982-04-28	1986-12-30	Beecham Group Plc	Chromènes et chromanes
IL86798A (en) *	1987-06-23	1992-12-01	Sanofi Sa	2,2-dimethylchroman-3-ol derivatives, their preparation and pharmaceutical compositions containing them
ATE120459T1 (de) *	1988-12-13	1995-04-15	Beecham Group Plc	Benzopyran und verwandte verbindungen.

1992
- 1992-12-01 CZ CZ941363A patent/CZ136394A3/cs unknown
- 1992-12-01 RU RU94030464/14A patent/RU94030464A/ru unknown
- 1992-12-01 WO PCT/GB1992/002234 patent/WO1993010757A1/fr not_active Ceased
- 1992-12-01 JP JP5509963A patent/JPH07501538A/ja active Pending
- 1992-12-01 EP EP92923956A patent/EP0615437A1/fr not_active Withdrawn
- 1992-12-01 CA CA002125156A patent/CA2125156A1/fr not_active Abandoned
- 1992-12-01 AU AU29542/92A patent/AU2954292A/en not_active Abandoned
- 1992-12-01 HU HU9401681A patent/HUT70745A/hu unknown
- 1992-12-01 SK SK657-94A patent/SK65794A3/sk unknown
- 1992-12-01 BR BR9206845A patent/BR9206845A/pt not_active Application Discontinuation
- 1992-12-03 IL IL103952A patent/IL103952A0/xx unknown
- 1992-12-03 MA MA23021A patent/MA22731A1/fr unknown
- 1992-12-03 MX MX9206975A patent/MX9206975A/es unknown
- 1992-12-04 AP APAP/P/1992/000454A patent/AP382A/en active
- 1992-12-04 SI SI19929200365A patent/SI9200365A/sl unknown

Also Published As

Publication number	Publication date
IL103952A0 (en)	1993-05-13
MX9206975A (es)	1993-06-01
HU9401681D0 (en)	1994-09-28
SI9200365A (en)	1993-06-30
CA2125156A1 (fr)	1993-06-10
AP382A (en)	1995-05-03
AU2954292A (en)	1993-06-28
BR9206845A (pt)	1996-01-02
JPH07501538A (ja)	1995-02-16
CZ136394A3 (en)	1995-02-15
AP9200454A0 (en)	1993-01-31
RU94030464A (ru)	1996-04-27
WO1993010757A1 (fr)	1993-06-10
HUT70745A (en)	1995-10-30
EP0615437A1 (fr)	1994-09-21
MA22731A1 (fr)	1993-07-01

Publication	Publication Date	Title
RU2327450C2 (ru)	2008-06-27	Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
TWI272106B (en)	2007-02-01	New medicament compositions based on anticholinergically-effective compounds and beta-mimetics
US6191153B1 (en)	2001-02-20	Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity
EP0277352B1 (fr)	1991-10-16	Association synergétique d'azélastine et de théophylline ou d'azélastine et de bêta-mimétiques
CA1336686C (fr)	1995-08-15	Methode de prevention ou de traitement des migraines au moyen d'un antagoniste du recepteur de la thromboxane a
EP1161949A1 (fr)	2001-12-12	Utilisation de diazepino-indoles dans le traitement des bronchopneumopathies chroniques obstructive
SK65794A3 (en)	1995-02-08	Pharmaceutical mixture, method of its preparing and using
EP1429768A1 (fr)	2004-06-23	Agents pharmaceutiques d'inhalation
AU657412B2 (en)	1995-03-09	Agent for increasing somatostatin or for inhibiting decrease of somatostatin
JPH07505381A (ja)	1995-06-15	気道炎症および気道過応答性の治療薬
KR20050094810A (ko)	2005-09-28	로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물
JP2002520364A (ja)	2002-07-09	治療方法
US6297268B1 (en)	2001-10-02	Imidazoles as cholesterol lowering agents
JPH0776584A (ja)	1995-03-20	内皮細胞障害抑制剤
WO2004084894A1 (fr)	2004-10-07	Combinaison synergetique comprenant du roflumilast et du revatropate destinee au traitement de maladies respiratoires
EP1411936A1 (fr)	2004-04-28	Utilisation de derives de thiazole pour la fabrication d'un medicament pour le traitement de la bronchopneumopathie chronique obstructive
AU2002317509B2 (en)	2007-03-08	Use of thiazole deirvatives for the manufacture of a medicament for the treatment of chronic obstructure pulmonary disease
JPH02286618A (ja)	1990-11-26	フイゾスチグミンおよびアレコリンの鼻内投与用製剤
JP2020203955A (ja)	2020-12-24	医薬組成物、医薬組成物の製造方法、及び非晶質体の安定性を向上させる方法
CN1080171A (zh)	1994-01-05	药用组合物
JPH06172173A (ja)	1994-06-21	肺高血圧症治療剤
HK1044884A1 (en)	2002-11-08	Treatment of chronic obstructive pulmonary disease with DIAZEPINOINDOLES
JPS58208230A (ja)	1983-12-03	抗腫瘍剤
AU2002317509A1 (en)	2003-05-29	Use of thiazole deirvatives for the manufacture of a medicament for the treatment of chronic obstructure pulmonary disease